The protective effect of taurine, piracetam and vinpocetine on etoposide-induced inflammation and brain injury in the serum of female albino rats

Etoposide (ETP) is one of the leading antitumour agents in cancer chemotherapy. Many studies have reported on ETP-induced peripheral neuropathy; however, few reports have focused on its brain toxicity. The current research investigates the protective potential of taurine, piracetam and vinpocetine o...

Full description

Saved in:
Bibliographic Details
Published in:Ecancermedicalscience 2023, Vol.17, p.1499-1499
Main Authors: Mohammed, Arwa Salam, Al-Hassani, Ansam N, Alrawi, Rafal Abdulrazaq, Tawfeeq, Rawaz D
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Cognitive enhancement
Cytokines
Cytotoxicity
Drug dosages
Enzymes
Experiments
Kinases
Laboratory animals
Neurological disorders
Neurotoxicity
Peripheral neuropathy
Pharmacy
Toxicity
Traumatic brain injury
Tumor necrosis factor-TNF
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Etoposide (ETP) is one of the leading antitumour agents in cancer chemotherapy. Many studies have reported on ETP-induced peripheral neuropathy; however, few reports have focused on its brain toxicity. The current research investigates the protective potential of taurine, piracetam and vinpocetine on serum biomarkers associated with inflammation and brain injury induced by ETP in a rodent model. A total of 30 female albino rats were equally divided into five groups; the 1 and 2 groups were the control and ETP-treated groups, respectively, while the 3 , 4 and 5 groups were ETP-treated rats cotreated with taurine, piracetam and vinpocetine, respectively. Administration of ETP reduced body weight significantly, enhanced production of serum proinflammatory cytokines including tumour necrosis factor-alpha, interleukin-1 beta (IL-1β) and IL-6 and decreased glutathione serum levels. Moreover, ETP treatment resulted in upregulation of glial fibrillary acidic protein expression and histopathological alterations in the rats' brain compared to the control group. Co-treatment with taurine, piracetam and vinpocetine counteracted ETP-induced brain injury and altered serum biomarkers levels. We concluded that co-treatment with vinpocetine could serve as a complementary therapeutic agent in reducing brain injury and toxicity induced by ETP.
ISSN:1754-6605
1754-6605
DOI:10.3332/ecancer.2023.1499